Takhzyro To Be Available at Lower Cost in Poland, Australia Likely as Well

Takhzyro To Be Available at Lower Cost in Poland, Australia Likely as Well

311093

Takhzyro To Be Available at Lower Cost in Poland, Australia Likely as Well

Takhzyro (lanadelumab), an approved under-the-skin injection therapy to prevent swelling attacks in people with hereditary angioedema (HAE), will soon be available at a lower cost to patients in Poland and, likely, those in Australia. Poland’s Minister of Health approved access to and reimbursement for Takhzyro for about 50 patients, according to a statement from HAE Poland. The approval will be valid until Sept. 1, 2023, and HAE Poland is hopeful that approvals will be extended…

You must be logged in to read/download the full post.